NO964015L - Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer - Google Patents

Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer

Info

Publication number
NO964015L
NO964015L NO964015A NO964015A NO964015L NO 964015 L NO964015 L NO 964015L NO 964015 A NO964015 A NO 964015A NO 964015 A NO964015 A NO 964015A NO 964015 L NO964015 L NO 964015L
Authority
NO
Norway
Prior art keywords
calpain
activation
detecting
identifying
inhibitors
Prior art date
Application number
NO964015A
Other languages
English (en)
Other versions
NO964015D0 (no
Inventor
Robert Siman
Donna Bozyzko-Coyne
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO964015L publication Critical patent/NO964015L/no
Publication of NO964015D0 publication Critical patent/NO964015D0/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelse tilveiebringer fremgangsmåter for påvisning av kalpain-aktivering ved måling av nivået av kalpain-genererte spektrin BDP'er ved anvendelse av anti- stoffer som spesifikt binder seg til disse spektrin BDP'er, men ikke til intakt spektrin, eller til spektrin BDP'er generert av andre proteaser. Også inkludert i denne oppfinnelse er en kit for diagnostisering av syk- dommer assosiert med øket nivå av kalpain-aktivering, og fremgangsmåter til screening for effektive terapeutika for disse sykdommer.
NO964015A 1994-03-25 1996-09-24 Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer NO964015D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,989 US5536639A (en) 1994-03-25 1994-03-25 Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
PCT/US1995/002279 WO1995026506A1 (en) 1994-03-25 1995-02-21 Methods for detecting calpain activation and indentifying calpain inhibitors

Publications (2)

Publication Number Publication Date
NO964015L true NO964015L (no) 1996-09-24
NO964015D0 NO964015D0 (no) 1996-09-24

Family

ID=22813313

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964015A NO964015D0 (no) 1994-03-25 1996-09-24 Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer

Country Status (8)

Country Link
US (2) US5536639A (no)
EP (1) EP0752103A1 (no)
JP (1) JPH09511332A (no)
AU (1) AU1929695A (no)
CA (1) CA2185141A1 (no)
FI (1) FI963811A0 (no)
NO (1) NO964015D0 (no)
WO (1) WO1995026506A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910564B1 (en) * 1995-11-28 2007-10-31 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
EP0799892A3 (en) * 1996-04-05 1998-08-12 Takeda Chemical Industries, Ltd. Calpain, its production and use
WO1998018485A1 (en) 1996-10-31 1998-05-07 Alcon Laboratories, Inc. The use of calpain inhibitors to treat ocular neural pathology
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
GB9704312D0 (en) * 1997-03-01 1997-04-23 Univ Nottingham Diagnostic assay
EP1116029B1 (en) * 1998-09-24 2007-12-26 Promega Corporation Apoptosis marker antibodies and methods of use
AU3194900A (en) * 1999-03-19 2000-10-09 Yamanouchi Pharmaceutical Co., Ltd. Method for screening cysteine protease inhibitor
AUPQ656500A0 (en) * 2000-03-28 2000-04-20 Autogen Pty Ltd A method of treatment and agents for same
US20020009740A1 (en) * 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
JP2005538380A (ja) * 2002-09-11 2005-12-15 ユニヴァーシティ オヴ フロリダ 神経細胞損傷の分析
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US7396654B2 (en) 2004-04-15 2008-07-08 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for traumatic brain injury
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
WO2008033575A2 (en) * 2006-09-15 2008-03-20 Metabolon, Inc. Methods of identifying biochemical pathways
WO2008097618A1 (en) * 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
CA2733990C (en) * 2008-08-11 2018-12-11 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118606A (en) * 1988-09-02 1992-06-02 The Regents Of The University Of California Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products
EP0564552A1 (en) * 1990-12-28 1993-10-13 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors

Also Published As

Publication number Publication date
US5536639A (en) 1996-07-16
FI963811A (fi) 1996-09-24
FI963811A0 (fi) 1996-09-24
NO964015D0 (no) 1996-09-24
US5871712A (en) 1999-02-16
EP0752103A1 (en) 1997-01-08
JPH09511332A (ja) 1997-11-11
WO1995026506A1 (en) 1995-10-05
CA2185141A1 (en) 1995-10-05
AU1929695A (en) 1995-10-17

Similar Documents

Publication Publication Date Title
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
NO973444L (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
KR950700414A (ko) 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
AU3538195A (en) Assays and devices for the detection of extrahepatic biliary atresia
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
DE69115267D1 (de) Antigen-/antiantigenspaltung.
NO982265L (no) Diagnostikk for og mediatorer for inflammatoriske forstyrrelser
DK0939651T3 (da) Materialer og metoder ved diagnose og behandling af præeclapsia
NO933146L (no) Fremgangsmåte ved undersökelse av Lupus antikoagulerende middel
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
DE59509344D1 (de) Antikörperklassenspezifisches entstörungsreagenz
NO974000D0 (no) Fremgangsmåte og forbindelser for påvisning av analytter, ved hjelp av remanensmålinger, samt anvendelse av slike forbindelser
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
FI973418A0 (fi) Vasta-ainetuotannon toteaminen
DK1171157T3 (da) Anvendelse af glucose-6-phosphat-isomerase og antistoffer derimod til diagnosticering og behandling af arthritis, og test for anti-arthritis-forbindelser
ATE280949T1 (de) Verfahren zur bestimmung der avidität von antikörpern
DK0786089T3 (da) Fremgangsmåde til vurdering af afsætning af Bacillus thuringiensis-delta-endotoxin
UA33566A (uk) Спосіб кількісного визначення ципрофлоксацину

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application